DUBLIN--(BUSINESS WIRE)--Jul 30, 2018--The "2018 Pulmonary Embolism Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Pulmonary Embolism Market" report has been added to ResearchAndMarkets.com's offering.

Pulmonary Embolism refers to a heart condition in the arteries transporting blood to the lungs are blocked, causing sudden shortness of breath and chest pain. The prevalence rates in the US are around 0.08%. Clinical symptoms of the disease include pulse less electrical activity to mild dyspnea. On the basis of severity, Pulmonary Embolism is classified as massive, sub-massive and low types. Anticoagulants are primarily administered to the patients.

To assist researchers, investors and business development managers, the publisher has come up with a comprehensive report on Pulmonary Embolism pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Pulmonary Embolism pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Pulmonary Embolism pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Companies Mentioned

Daiichi Sankyo Co Ltd Dong-A Socio Holdings ST Pharm Co.,Ltd. Tasly Phar. International Co., Ltd TeaRx Ltd. Verseon Corp

Key Topics Covered:

1 Table of Contents

2 Pulmonary Embolism Pipeline Analysis

3 Pulmonary Embolism- Company Wise Pipeline Analysis

4 Pulmonary Embolism R&D Pipeline Snapshots

5 Recent Developments in Pulmonary Embolism Pipeline

6 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/6j2p38/pulmonary?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180730005318/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Drug Discovery,Cardiovascular Drugs ,Clinical Trials

KEYWORD:

INDUSTRY KEYWORD: HEALTH CARDIOLOGY CLINICAL TRIALS PHARMACEUTICAL RESEARCH SCIENCE

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 07/30/2018 06:38 AM/DISC: 07/30/2018 06:38 AM

http://www.businesswire.com/news/home/20180730005318/en